Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Marina Biotech, Inc. Announces Upcoming Investor Conference Presentations

July 29, 2010 5:45 am | by The Associated Press | News | Comments

Marina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that J. Michael French, Marina's President and Chief Executive Officer, will provide an overview of the Company and its progress in key...

Vitamin D deficiency linked to arterial stiffness in black teens

July 29, 2010 4:41 am | by EurekAlert | News | Comments

(The Endocrine Society) Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism. Black teens...

TOPICS:

ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24

July 29, 2010 4:37 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO , July 29 /- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks...

TOPICS:
Advertisement

Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount

July 29, 2010 4:37 am | by Bio-Medicine.Org | News | Comments

MARLTON, N.J. , July 29 /- Free For All® Inc., MMM Healthcare, Inc. (MMM) and PMC Medicare Choice, Inc. today announced a plan to offer MMM/PMC members access to medications, lab testing and medical imaging at substantial rate reductions with the use of RxCut®Plus cards. The...

TOPICS:

Winner Medical Launches Its First Online PurCotton(R) Store in China on Taobao.com

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

SHENZHEN, China , July 29 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: WWIN ) ("Winner," or "the Company"), a leading manufacturer of medical dressings, medical disposables and non-woven PurCotton(R) materials for the medical and consumer products industries, announced today...

TOPICS:

IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif. , July 29 /- IRIDEX Corporation (Nasdaq: IRIX ) today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of...

TOPICS:

Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO , July 29 /- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, will announce its second quarter ended June 30, 2010 financial results on Thursday, August 5, 2010 after the markets close. The announcement will be...

TOPICS:

AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH®

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

WOBURN, Mass.and VEDBAEK, Denmark , July 29 /- AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its Yeast Traffic Light® PNA FISH® test.  The faster protocol reduces the PNA FISH turn-around time from the original 2.5...

TOPICS:
Advertisement

BD Announces Promotion of President Vince Forlenza; Gains Additional Title of Chief Operating Officer

July 29, 2010 4:33 am | by Becton, Dickinson and Company | News | Comments

(July 28, 2010) -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the promotion of Vincent A. Forlenza, President, who assumes the title of Chief Operating Officer in addition to his current title. Mr. Forlenza

TOPICS:

Integra LifeSciences 2Q profit rises 35 percent

July 29, 2010 3:45 am | by The Associated Press | News | Comments

Medical device maker Integra LifeSciences Holdings Corp. said Thursday its profit grew 35 percent in the second quarter as product sales increased, and the company took fewer charges.The company said its profit rose to $15.2 million, or 50 cents per share, from $11.2 million, or 38 cents per...

New lab test could identify imatinib resistance

July 28, 2010 10:35 pm | by EurekAlert | News | Comments

(American Association for Cancer Research) Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia.

TOPICS:

Glucose Monitors Get Under the Skin

July 28, 2010 8:34 pm | by Massachusetts Institute of Technology | News | Comments

Implantable devices work in diabetic pigs for over a year--human tests could be next.

TOPICS:

Bruker 2Q profit rises 75 pct on higher revenue

July 28, 2010 2:45 pm | by The Associated Press | News | Comments

Shares of Bruker Corp. rose Wednesday after the maker of scientific instruments reported a 75 percent increase in second-quarter profits as revenue climbed.The company earned $22.6 million, or 14 cents per share, compared with $12.9 million, or 8 cents per share, in the same period a year...

Best hope for saving Arctic sea ice is cutting soot emissions, says Stanford researcher

July 28, 2010 2:43 pm | by EurekAlert | News | Comments

(Stanford University) Soot from the burning of fossil fuels and solid biofuels contributes far more to global warming than has been thought, according to a new Stanford study. But, unlike carbon dioxide, soot lingers only a few weeks in the atmosphere, so cutting emissions could...

TOPICS:

Huntington's disease discovery provides new hope for treatment

July 28, 2010 2:43 pm | by EurekAlert | News | Comments

(University of Melbourne) Australian scientists have identified the behavior of the mutant protein "huntingtin" which leads to the fatal Huntington's disease providing potential targets to treat the disease, a University of Melbourne study reveals.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading